Abaloparatide: Tymlos bone-building drug for osteoporosis
A synthetic peptide that stimulates new bone growth in people with osteoporosis at high fracture risk; FDA-approved drug (brand name Tymlos).
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Abaloparatide (brand name Tymlos; development code BA058) is an FDA-approved prescription medication used to build new bone in people with osteoporosis who are at high risk of fracture. It is a synthetic 34-amino-acid peptide designed to mimic a natural protein called parathyroid hormone-related protein (PTHrP), which the body uses to regulate bone and calcium. Unlike most osteoporosis drugs that slow bone loss, abaloparatide actively stimulates bone formation — it is one of only three "anabolic" (bone-building) agents approved by the FDA. The FDA approved it in April 2017 for postmenopausal women with osteoporosis at high fracture risk, and extended that approval to men with osteoporosis in 2022. The sequence stored in this card (44 residues, ending in GSGSSC) is longer than the canonical 34-residue approved drug; the C-terminal extension appears to derive from a construct used in a laboratory study and is not part of the commercial abaloparatide molecule, which ends at position 34.
History
The story of abaloparatide begins with the PTH type-1 receptor (PTH1R), which was established in the 1990s as a promising target for osteoporosis therapy. A key insight emerged from studying primary hyperparathyroidism: continuously elevated PTH drives net bone resorption and calcium release, but when PTH was given in brief daily pulses, bone formation actually exceeded resorption — the drug teriparatide (PTH 1–34) was built on this pulsatile-activation principle and approved in 2002.
Parathyroid hormone-related protein (PTHrP) is a separate hormone that acts on the same PTH1R receptor, but its normal physiological role is local and paracrine — guiding fetal bone and cartilage development, modulating breast and smooth-muscle tissue — rather than controlling systemic calcium. Early research showed that PTHrP(1–34) activated PTH1R with shorter-lived signaling than PTH(1–34), and produced less hypercalcemia at comparable doses in preclinical studies. Radius Health (then a partnership with Ipsen) engineered abaloparatide as an optimized analog of PTHrP(1–34) with amino acid substitutions tuned to enhance receptor affinity and pharmacokinetic stability.
The molecular basis for abaloparatide's distinct behavior was characterized by Hattersley and colleagues (Endocrinology, 2016): abaloparatide binds PTH1R with approximately 10-fold preference for the active RG conformation over the inactive R0 conformation, whereas teriparatide binds both conformations with roughly equal affinity. This conformational selectivity translates to more transient intracellular signals per injection and, hypothetically, a broader anabolic window with less osteoclast-activating follow-through.
The pivotal Phase 3 ACTIVE trial (Miller et al., JAMA 2016) randomized 2,463 postmenopausal women with osteoporosis across 28 sites in 10 countries over 18 months and formed the basis for FDA approval on April 28, 2017. The ACTIVExtend trial then examined sequential transition to alendronate after the abaloparatide course. A subsequent trial in men (ATOM) established the male indication approved in 2022. The original class boxed warning for osteosarcoma risk — based on rat carcinogenicity data shared with teriparatide — was removed by the FDA in 2022 after accumulated post-marketing surveillance in humans showed no osteosarcoma signal.
What it does
Abaloparatide stimulates bone-building cells (osteoblasts) to lay down new bone faster than bone-removing cells (osteoclasts) remove it. This is the opposite of how most osteoporosis medications work: bisphosphonates and denosumab mainly slow the removal of bone, while abaloparatide actively increases formation. The result is measurable bone density gains at the spine and hip, and a reduction in fracture risk, within months of starting treatment.
The key design feature is abaloparatide's preference for the active (RG) conformation of the PTH1R receptor. Binding this conformation produces a shorter burst of intracellular cAMP signaling per injection compared to teriparatide — a more transient pulse that drives osteoblast activity without the prolonged cAMP tail that tends to also activate osteoclasts and raise calcium. This mechanistic difference is hypothesized to explain the clinical observation that abaloparatide causes less transient hypercalcemia than teriparatide.
In the ACTIVE trial, abaloparatide produced mean lumbar spine bone mineral density (BMD) gains of approximately 11% from baseline at 18 months, versus 0.6% for placebo (Miller et al., JAMA 2016). Hip BMD gains were significantly faster than with teriparatide at 6 months. A notable property of all PTH1R anabolic agents is that BMD gains are largely reversed after discontinuation unless an antiresorptive drug (bisphosphonate or denosumab) is started to consolidate them — this sequencing is standard clinical practice.
Evidence
- Human: Extensive. The pivotal ACTIVE Phase 3 trial (n=2,463 postmenopausal women, 18 months) showed an 86% reduction in new vertebral fractures versus placebo (0.58% vs 4.22%, P<0.001) and a 43% reduction in nonvertebral fractures (HR 0.57, P=0.049) (Miller et al., JAMA 2016). Hypercalcemia occurred in 3.4% of abaloparatide patients versus 6.4% with teriparatide (P=0.006). The ACTIVExtend trial showed that transitioning to alendronate after the abaloparatide course preserved and extended fracture-risk reduction over an additional 24 months. The ATOM trial established BMD gains and safety in men with osteoporosis, supporting the male indication approved in 2022. Multiple meta-analyses and network meta-analyses have examined abaloparatide in the broader context of available osteoporosis therapies.
- Preclinical: Comprehensive. Ovariectomized-rat, orchiectomized-rat, and other animal models characterized abaloparatide's anabolic effect and confirmed the mechanistic RG-conformation selectivity story described by Hattersley and colleagues (Endocrinology, 2016).
- In vitro: The RG vs R0 PTH1R binding-selectivity experiments used competitive radioligand binding and cAMP reporter assays in PTH1R-expressing HEK293 cells (Hattersley et al., Endocrinology 2016), establishing the molecular pharmacology that underlies the clinical differentiation from teriparatide.
Known effects
- Reduction in vertebral fracture risk — FDA-approved (Phase 3 ACTIVE trial)
- Reduction in nonvertebral fracture risk — FDA-approved
- Bone mineral density gain at lumbar spine, total hip, femoral neck — FDA-approved; well-characterized in ACTIVE
- Lower rate of treatment-emergent hypercalcemia vs teriparatide — Demonstrated in ACTIVE (3.4% vs 6.4%, P=0.006)
- Bone-building effect in men with osteoporosis — FDA-approved (ATOM trial)
- Preservation of BMD gains with sequential antiresorptive — Demonstrated in ACTIVExtend
Safety signals
Injection-site reactions were the most common adverse event in the ACTIVE trial (57.8% with abaloparatide vs 11.9% with placebo), predominantly mild. Nausea and dizziness occurred in approximately 10% each with abaloparatide. A transient increase in heart rate of approximately 8 beats per minute within one hour of dosing was observed; cardiovascular safety analysis from the ACTIVE trial did not identify increased serious cardiac events. Transient hypercalcemia was significantly less frequent with abaloparatide than with teriparatide (3.4% vs 6.4%, P=0.006 in ACTIVE). Orthostatic hypotension — a blood-pressure drop on standing — can occur shortly after injection, particularly after the first dose.
The original boxed warning for osteosarcoma risk (derived from Fischer 344 rat carcinogenicity studies at high doses) was removed by the FDA in 2022, alongside the equivalent teriparatide warning, based on accumulated post-marketing surveillance data showing no human osteosarcoma signal. Labeled contraindications for patients at baseline elevated osteosarcoma risk — those with Paget's disease of bone, prior skeletal radiation therapy, unexplained elevated alkaline phosphatase, or open bone growth plates (pediatric or young adult patients) — remain in force as class-level cautions.
Regulatory status
- US: FDA-approved prescription drug (Tymlos). Initial approval April 28, 2017 for postmenopausal women with osteoporosis at high fracture risk; extended to men with osteoporosis in 2022. The original boxed warning for osteosarcoma and a prior cumulative lifetime use restriction were removed by the FDA in 2022. Not a controlled substance; distributed through specialty pharmacies.
- EU: The original EMA marketing authorization application was withdrawn following a negative CHMP opinion in 2018. Subsequently approved by the UK MHRA in 2022 and available in several other European markets via national pathways or subsequent applications.
- Canada: Health Canada approved.
- WADA: Abaloparatide is not specifically named on the WADA Prohibited List; its anabolic bone pharmacology and PTH1R-axis activity would draw doping-program scrutiny for performance-related off-label use.
Myths and misconceptions
- "Abaloparatide is just a modified teriparatide and works the same way" — While both activate PTH1R, the conformational selectivity difference produces clinically relevant distinctions: abaloparatide causes significantly less hypercalcemia (3.4% vs 6.4%, P=0.006 in ACTIVE) and showed faster hip BMD gains at 6 months. Abaloparatide is also a PTHrP-derived analog, not a PTH-derived one — a different parent peptide engineered to a different receptor binding profile. It is a brand-name drug (Tymlos), not a biosimilar or generic.
- "Two years of abaloparatide will permanently build bone" — BMD gains are substantially reversed after stopping unless an antiresorptive agent is started. The ACTIVExtend trial was designed specifically to demonstrate the sequential anabolic-then-antiresorptive paradigm: patients who transitioned to alendronate after abaloparatide maintained fracture-risk reduction through the antiresorptive period; stopping without the antiresorptive bridge allows gains to erode.
- "Abaloparatide causes osteosarcoma in humans" — The original boxed warning derived from rat carcinogenicity studies at high lifetime doses. Post-marketing surveillance following years of teriparatide use (approved 2002) and abaloparatide use identified no human osteosarcoma signal. The FDA removed the boxed warning and cumulative use restriction in 2022. Class-specific baseline-risk contraindications (Paget's disease, prior bone radiation, open growth plates) remain.
- "Abaloparatide is safer than teriparatide overall" — The lower hypercalcemia rate is real and mechanistically grounded, but the two drugs share the same class cautions, overlapping adverse-event profiles, and broadly similar safety considerations. The choice between them in clinical practice typically involves access, cost, injection-device preferences, and individual patient calcium-monitoring context rather than a blanket safety advantage for either.
Common questions
How does abaloparatide compare to romosozumab (Evenity)? Romosozumab is an anti-sclerostin monoclonal antibody that works by a distinct mechanism — it inhibits sclerostin, unlocking the Wnt/β-catenin pathway to simultaneously increase bone formation and reduce resorption. Unlike abaloparatide's daily injection schedule, romosozumab is given monthly for 12 months. The ARCH trial showed romosozumab followed by alendronate reduced vertebral fractures more than alendronate alone; romosozumab's label carries a cardiovascular warning (increased risk in patients with prior stroke or MI). No head-to-head randomized trial has compared abaloparatide and romosozumab directly on fracture outcomes.
Can abaloparatide be used in men with osteoporosis? Yes. The ATOM trial enrolled men with osteoporosis and showed BMD gains consistent with results in women from the ACTIVE trial. The FDA extended the Tymlos indication to include men in 2022.
Is there a non-injection form of abaloparatide? A transdermal microneedle-patch formulation (abaloparatide-sMTS) was evaluated in a Phase 3 trial but did not meet non-inferiority versus subcutaneous injection for the primary BMD endpoint. Development of this route continues; the only currently approved formulation is subcutaneous injection.
Related peptides
- Teriparatide — PTH(1–34); the first PTH1R anabolic agent for osteoporosis (approved 2002); binds both RG and R0 receptor conformations with similar affinity; associated with higher rates of transient hypercalcemia compared to abaloparatide in the ACTIVE trial
- BPC-157 — a synthetic peptide studied for tissue repair and gastric protection; mechanistically unrelated to PTH1R signaling
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
If abaloparatide is placed directly at a fracture site rather than injected into the bloodstream, could it stimulate faster bone repair without raising dangerous calcium levels?
This could provide surgeons with a tool to accelerate healing of difficult fractures in osteoporotic patients, reducing the rate of failed fixation, repeat surgeries, and disability in an aging population.
Does abaloparatide lock onto its receptor in a particular shape that stimulates bone building while avoiding the bone-breakdown signal that limits other drugs?
Understanding this mechanism could explain why abaloparatide builds bone faster than teriparatide, and could guide the design of even better osteoporosis drugs that build bone without the two-year safety limit imposed on current treatments.
Is the mysterious position-26 residue in abaloparatide a helix-stiffening modification that makes the peptide latch onto its bone receptor faster and more strongly?
Identifying this key structural feature would provide a blueprint for engineering the next generation of bone-building drugs with even greater potency, potentially helping patients who do not respond adequately to current treatments.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.7607945799827576 | openfold3-mlx |
| ranking score | 0.9019421339035034 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.782 | global PDE — lower = better |
| disorder | 0.323 | ! high disorder |
| chain pair ipTM (A, B) | 0.761 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | — |
| hardware | — |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | — |
| diffusion samples | 1 |
| runtime | 835s |
| predicted by | mlx@peptide |
| predicted at | 2026-05-03 |
▸citationbibtex
@peptide{pep10888,
sequence = {AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHADLRTRGSGSSC},
target = {pth1r},
author = {peptidemodel},
year = {2026},
status = {computed}
}